- Home
- LXRX vs INMD Comparison
LXRX vs INMD Comparison
Compare LXRX & INMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXRX | INMD |
|---|---|---|
| Founded | 1995 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 990.6M | 842.0M |
| IPO Year | 2000 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LXRX | INMD |
|---|---|---|
| Price | $2.34 | $15.11 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 5 |
| Target Price | $4.15 | ★ $17.33 |
| AVG Volume (30 Days) | ★ 2.7M | 614.2K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.78 | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $49,803,000.00 | N/A |
| Revenue This Year | N/A | $1.74 |
| Revenue Next Year | N/A | $3.26 |
| P/E Ratio | ★ N/A | $10.11 |
| Revenue Growth | ★ 60.24 | N/A |
| 52 Week Low | $1.02 | $12.72 |
| 52 Week High | $2.68 | $16.74 |
Technical Indicators
Market Signals| Indicator | LXRX | INMD |
|---|---|---|
| Relative Strength Index (RSI) | 53.49 | 55.37 |
| Support Level | $2.04 | $13.27 |
| Resistance Level | $2.61 | $15.23 |
| Average True Range (ATR) | 0.15 | 0.31 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 65.12 | 36.20 |
Price Performance
Historical ComparisonAbout LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About INMD InMode Ltd.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.